Modality
Bispecific Ab
MOA
FXIai
Target
GIP-R
Pathway
Ferroptosis
NB
Development Pipeline
Preclinical
Dec 2023
→ Nov 2027
PreclinicalCurrent
NCT07608514
444 pts·NB
2023-12→2027-11·Completed
444 total pts1 indication
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-011.6y awayInterim· NB
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
Preclinical
Complet…
Catalysts
Interim
2027-11-01 · 1.6y away
NB
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07608514 | Preclinical | NB | Completed | 444 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Ivotuximab | GSK | NDA/BLA | GIP-R | |
| TAK-8730 | Takeda | Phase 2 | VEGF |